John Moscona
Interventional Cardiology · Austin, TXNPI 1710202916
Payments from drug & device makers
Across 217 payments — averaging $343.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$41K
- Medtronic$21K
- Boston Scientific$11K
- Edwards Lifesciences$580
- Cardiovascular Systems Inc.$463
- Shockwave Medical, Inc$258
- plus $1K from 16 others
What the payments were for
- Consulting fees$1,5505%
- Speaking & faculty fees$18,66059%
- Travel & lodging$3,41911%
- Food & beverage$7,82625%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 62 | $40,829 |
| Medtronic(2 entities) | 83 | $20,628 |
| Boston Scientific | 23 | $10,854 |
| Edwards Lifesciences | 12 | $580 |
| Cardiovascular Systems Inc. | 4 | $463 |
| Shockwave Medical, Inc | 3 | $258 |
| Asahi Intecc USA, Inc. | 3 | $234 |
| Celonova Biosciences, Inc. | 1 | $227 |
| Abiomed | 3 | $90 |
| Inari Medical, Inc. | 3 | $83 |
| Acist Medical Systems, Inc. | 3 | $66 |
| Impulse Dynamics (USA) Inc. | 3 | $55 |
| Pfizer | 2 | $53 |
| Terumo Medical Corporation | 2 | $44 |
| Novo Nordisk | 2 | $44 |
| Johnson & Johnson | 1 | $26 |
| Philips North America LLC | 2 | $24 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $23 |
| Penumbra, Inc. | 1 | $20 |
| Endovascular Engineering Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$18,769
- NAVITOR$3,835
- GUIDEZILLA$800
- SYNERGY$389
- MitraClip$297
- GENERAL VASCULAR ACCESS$295
- Peripheral Orbital Atherectomy System$295
- Coronary Orbital Atherectomy System$295
- Dragonfly OCT$283
- GENERAL - THERAPIES$277
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$188
- CROSSBOSS$184
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$181
- DRAGONFLY OPSTAR$165
- ASAHI PTCA Guide Wire$126
- CoreValve Evolut$122
- Diamondback Coronary$106
How this compares
$74,647 in reported general payments places this provider in the 80th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $37,419 |
| JardianceEmpagliflozin | 27 | $30,654 |
| XareltoRivaroxaban | 20 | $24,261 |
| Prasugrel Hcl | 44 | $2,708 |
| ClopidogrelClopidogrel Bisulfate | 132 | $1,850 |
| Atorvastatin Calcium | 118 | $1,089 |
| Metoprolol Succinate | 49 | $909 |
| Ezetimibe | 53 | $749 |
| Losartan Potassium | 55 | $734 |
| Potassium Chloride | 31 | $678 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 22 | $496 |
| Irbesartan | 21 | $432 |
| Rosuvastatin Calcium | 57 | $424 |
| Chlorthalidone | 25 | $362 |
| Amlodipine Besylate | 31 | $294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $53 | $37,41929 claims |
| Boehringer IngelheimJardiance | $15 | $30,65427 claims |
| Johnson & JohnsonXarelto | $26 | $24,26120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Austin
- Mark PirwitzAustin$2.4M
- Francis ZidarAustin$1.8M
- Juhana KarhaAustin$842K
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.